We profiled six PDX samples from B-ALL patients with KMT2A rearrangements (KMT2A-r PDX) (Supplementary Table 1), a high-risk subtype often showing lineage switch or CD19 loss following CD19-targeted immunotherapy. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.